Medical Aesthetic Filler segmentation by type distinguishes five chemically distinct families that together define the market’s revenue structure. Hyaluronic acid (HA) fillers dominate, representing roughly 55 % of global sales because of their reversible nature, broad viscosity range, and established safety profile; they serve both superficial lines and deep volumizing needs. Calcium hydroxylapatite (CaHA) occupies about 15 % of the market, valued for its biostimulatory collagen‑inducing effect and longer persistence, positioning it in mid‑to‑high volume restoration. Poly‑L‑lactic acid (PLLA) accounts for near 10 % and is classified as a biostimulatory agent that gradually replaces lost tissue, attracting clinicians focused on progressive rejuvenation. Polymethylmethacrylate (PMMA) micro‑beads, with roughly 5 % share, are permanent fillers used in scar correction and deep‑line treatment, limiting their uptake due to regulatory scrutiny. Autologous fat grafting, contributing the remaining 15 % share, leverages patient‑derived tissue, offering unlimited volume but requiring surgical harvest. Collectively, these sub‑types shape the overall Medical Aesthetic Filler market size by aligning product characteristics with practitioner preferences and reimbursement frameworks.
